Study wrapper · #747
MOTS-C levels ın ındividuals with and without obesity and ıts association with ınflammation, insulin resistance and endothelial dysfunction.
Editor's note
This cross-sectional study measured serum MOTS-c in 48 adults with obesity and 37 with normal BMI, alongside markers of insulin resistance, inflammation, and endothelial function. It found no significant difference in MOTS-c between groups, but a positive correlation with insulin resistance (HOMA-IR); regression flagged age (inverse) and HOMA-IR (positive) as determinants. This is observational and cannot establish causation. It directly contradicts reports of clearly elevated (or reduced) MOTS-c in obesity, underscoring how inconsistent the human MOTS-c-obesity literature is. Publishable precisely because a well-reported null adds needed balance: MOTS-c may track insulin resistance more than adiposity itself, and no strong obesity signal emerged here. Weight it as one data point in a genuinely mixed evidence base.
Plain-language abstract
Researchers measured MOTS-c, a mitochondria-derived peptide tied to metabolism, in 85 adults, 48 with obesity and 37 of normal weight, and compared it against markers of insulin resistance, inflammation, and blood-vessel function. Unlike some earlier reports, they found no meaningful difference in blood MOTS-c between the two weight groups. However, MOTS-c did rise with insulin resistance, and further analysis suggested it decreases with age but increases with higher insulin resistance. It did not correlate with the inflammation or blood-vessel markers. Because this looked at everyone at a single point in time, it cannot show cause and effect. Notably, its "no difference by weight" result conflicts with other studies that found MOTS-c higher or lower in obesity, showing the science here is genuinely mixed. The useful message is that MOTS-c may relate more to insulin resistance and age than to body weight itself, and that findings across studies do not yet agree.